Skip to main content

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-799 trial

Salma Jabbour discusses the KEYNOTE-799 study of pembrolizumab plus concurrent chemoradiotherapy in nonresectable stage III non-small-cell lung cancer patients (6:54).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits